Proteomic Biomarkers of Sacubitril/Valsartan Treatment Response in Heart Failure With Preserved Ejection Fraction: Molecular Insights Into Sex Differences.
作者信息
Nguyen Thanh Thanh L, Wang Min, Liu Duan, Iyer Seethalakshmi, Gonzalez Bonilla Hilda Mariana, Acker Nancy, Murthy Vishakantha, Shrivastava Sanskriti, Desai Viral, Burnett John C, Redfield Margaret, Bailey Kent R, Weinshilboum Richard M, Pereira Naveen L
机构信息
Department of Molecular Pharmacology and Experimental Therapeutics (T.T.L.N., D.L., V.M., R.M.W., N.L.P.), Mayo Clinic, Rochester, MN.
Graduate School of Biomedical Sciences (T.T.L.N.), Mayo Clinic, Rochester, MN.
出版信息
Circ Heart Fail. 2022 Sep;15(9):e009629. doi: 10.1161/CIRCHEARTFAILURE.122.009629. Epub 2022 Jun 3.
Abstract
摘要
相似文献
1
Proteomic Biomarkers of Sacubitril/Valsartan Treatment Response in Heart Failure With Preserved Ejection Fraction: Molecular Insights Into Sex Differences.沙库巴曲缬沙坦治疗射血分数保留的心力衰竭反应的蛋白质组学生物标志物：性别差异的分子见解
Circ Heart Fail. 2022 Sep;15(9):e009629. doi: 10.1161/CIRCHEARTFAILURE.122.009629. Epub 2022 Jun 3.
2
Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction.沙库巴曲缬沙坦对射血分数保留心力衰竭患者血脂的影响。
J Am Heart Assoc. 2021 Sep 7;10(17):e022069. doi: 10.1161/JAHA.121.022069. Epub 2021 May 16.
3
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.沙库巴曲缬沙坦对射血分数保留的心力衰竭患者氨基末端 B 型利钠肽前体的影响。
JACC Heart Fail. 2020 May;8(5):372-381. doi: 10.1016/j.jchf.2020.03.002. Epub 2020 Mar 30.
4
Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF.沙库巴曲缬沙坦对 HFpEF 患者细胞外基质调节生物标志物的影响。
J Am Coll Cardiol. 2020 Aug 4;76(5):503-514. doi: 10.1016/j.jacc.2020.05.072.
5
Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.在评估心力衰竭（EVALUATE-HF）研究中，沙库巴曲缬沙坦与依那普利对心力衰竭患者的血流动力学影响：左心室射血分数和性别的效应修正
Circ Heart Fail. 2021 Mar;14(3):e007891. doi: 10.1161/CIRCHEARTFAILURE.120.007891. Epub 2021 Mar 5.
6
Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.沙库巴曲缬沙坦对比标准药物治疗对射血分数保留心力衰竭患者血浆 NT-proBNP 浓度和亚极量运动能力的影响：PARALLAX 随机临床试验。
JAMA. 2021 Nov 16;326(19):1919-1929. doi: 10.1001/jama.2021.18463.
7
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.沙库巴曲缬沙坦治疗射血分数降低的心力衰竭患者的效果：一项随机临床试验。
JAMA Cardiol. 2022 Jan 1;7(1):17-25. doi: 10.1001/jamacardio.2021.4567.
8
Response by Jackson et al to Letter Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF".杰克逊等人对关于文章《沙库巴曲缬沙坦与缬沙坦对射血分数保留的心力衰竭女性与男性的影响：PARAGON-HF研究的见解》的信件的回应
Circulation. 2020 Jul 7;142(1):e5-e6. doi: 10.1161/CIRCULATIONAHA.120.047275. Epub 2020 Jul 6.
9
Letter by Wu and Zhao Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF".吴和赵就“沙库巴曲缬沙坦与缬沙坦对射血分数保留的心力衰竭女性与男性的影响：PARAGON-HF研究的见解”一文所写的信。
Circulation. 2020 Jul 7;142(1):e3-e4. doi: 10.1161/CIRCULATIONAHA.119.045382. Epub 2020 Jul 6.
10
The Effect of Sacubitril/Valsartan on Left Ventricular Myocardial Deformation in Heart Failure with Preserved Ejection Fraction (PARAMOUNT trial).沙库巴曲缬沙坦对射血分数保留心力衰竭患者左心室心肌变形的影响（PARAMOUNT 试验）。
J Card Fail. 2023 Jun;29(6):968-973. doi: 10.1016/j.cardfail.2023.03.019. Epub 2023 Apr 7.
引用本文的文献
1
Effect of Neprilysin Inhibition on Plasma Proteins in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.中性肽链内切酶抑制对射血分数轻度降低或保留的心力衰竭患者血浆蛋白的影响。
JACC Heart Fail. 2025 Jun 17;13(8):102502. doi: 10.1016/j.jchf.2025.04.012.
2
Cardiac Fibrosis in the Multi-Omics Era: Implications for Heart Failure.多组学时代的心脏纤维化：对心力衰竭的影响
Circ Res. 2025 Mar 28;136(7):773-802. doi: 10.1161/CIRCRESAHA.124.325402. Epub 2025 Mar 27.
3
The interplay between sex, time of day, fasting status, and their impact on cardiac mitochondrial structure, function, and dynamics.性别、时间、禁食状态及其对心脏线粒体结构、功能和动力学的影响之间的相互作用。
Sci Rep. 2023 Dec 7;13(1):21638. doi: 10.1038/s41598-023-49018-z.
4
Loop diuretic management after sacubitril/valsartan initiation in heart failure with preserved ejection fraction: deceptively simple or more than meets the eye?射血分数保留的心力衰竭患者起始使用沙库巴曲缬沙坦后袢利尿剂的管理：看似简单实则暗藏玄机？
Eur J Heart Fail. 2023 Jan;25(1):95-97. doi: 10.1002/ejhf.2750. Epub 2022 Dec 14.
本文引用的文献
1
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.沙库巴曲缬沙坦对射血分数保留的心力衰竭患者氨基末端 B 型利钠肽前体的影响。
JACC Heart Fail. 2020 May;8(5):372-381. doi: 10.1016/j.jchf.2020.03.002. Epub 2020 Mar 30.
2
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.沙库巴曲缬沙坦与缬沙坦对射血分数保留心力衰竭女性与男性患者的影响：PARAGON-HF 研究的见解。
Circulation. 2020 Feb 4;141(5):338-351. doi: 10.1161/CIRCULATIONAHA.119.044491. Epub 2019 Nov 17.
3
Dynamic Changes in the Molecular Signature of Adverse Left Ventricular Remodeling in Patients With Compensated and Decompensated Chronic Primary Mitral Regurgitation.慢性原发性二尖瓣反流患者左心室重构不良的分子特征的动态变化：代偿期与失代偿期的比较。
Circ Heart Fail. 2019 Sep;12(9):e005974. doi: 10.1161/CIRCHEARTFAILURE.119.005974. Epub 2019 Sep 12.
4
Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies.不同病因心力衰竭患者的生化和遗传生物标志物差异。
Int J Cardiol. 2016 Oct 15;221:1073-80. doi: 10.1016/j.ijcard.2016.07.150. Epub 2016 Jul 12.
5
Shedded neuronal ICAM-5 suppresses T-cell activation.脱落的神经元ICAM-5抑制T细胞活化。
Blood. 2008 Apr 1;111(7):3615-25. doi: 10.1182/blood-2007-09-111179. Epub 2008 Jan 25.
Zotero 插件